Abstract: An exosome hydrogel for treating severe respiratory diseases is provided and includes a temperature-sensitive hydrogel and an exosome; wherein the temperature-sensitive hydrogel is PLGA-PEG-PLGA. According to the present invention, PLGA-PEG-PLGA generates a hydrogel exosome through a phase transition at a body temperature, and the hydrogel stays in lungs for a longer time than common exosomes, thereby making the exosome remain at an infection site and producing a better therapeutic effect. The exosome hydrogel features high safety, is suitable for promotion, and has good potential in medical treatment.

Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-5N-(methyl-d3)pyridazine-3-carboxamide of the formula: Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

Abstract: The method of preparing polyethyleneimine-lipid nanoparticles (PEI-LNPs) for transfecting stem cells includes the following steps: S1, adding anhydride to a PEI solution to produce polycarboxylic acid; S2, dissolving the PEI-LNPs from S1, together with DPPC, DPPG, DPPE-PEG-COOH and cholesterol in chloroform, dissolving cGAMP in a water and then adding to such chloroform solution, and performing vacuum evaporation to remove the chloroform; S3, adding PBS for hydration, and performing ultrasonication to obtain liposomes; and S4, adding EDC/NHS to the liposome solution obtained for reaction for 15 min, then adding mRNA, and stirring the mixed solution to obtain a bionic virus nanovaccine. The prepared PEI-LNPs are used for delivering an mRNA vaccine and transfecting stem cells, wherein through a lipid PEI derivative library synthesized based on short-branched PEI with a variable length and hydrophobic tail substitution ratio, short-branched PEI can form a stable complex with the mRNA vaccine.

Abstract: A method for preparing an atomizing SARS-CoV-2 nanovaccine includes the followings steps: mimicking a structure of SARS-COV-2 with receptor binding domains (RBDs) of SARS-COV-2, by taking Poly(I:C) mimicking viral genetic materials as an immunoadjuvant, and electronegative liposomes that enter pulmonary macrophages efficiently as a viral capsid structure; adding a catalyst and an RBD antigen protein to a liposome solution, linking the antigen protein to a liposome surface, and obtaining a bionic virus nanovaccine after purification and freeze-drying treatment. Compared with conventional intramuscular and subcutaneous inoculation, the SARS-CoV-2 vaccine of the present invention features strong mucosal protection effect, high safety, extensive application, and excellent potential.

Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.

Abstract: The disclosure describes chiral P(V)-based reagents and their uses for the modular, scalable, and stereospecific synthesis of chiral phosphines, phosphine oxides and particular oligonucleotides.

Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.

Abstract: The present invention discloses an anti-hair loss and hair growth integrated core-shell microneedle patch, comprising a backing and a core-shell microneedle array attached to one side of the backing, the core-shell microneedle array comprises a plurality of microneedles arranged on the backing to form an array, each microneedle comprises a shell substrate material and an internal core, and the shell substrate material is loaded with nano-enzyme for removing excessive active oxygen.

Abstract: The present invention discloses a nano-armored single cell product, comprising a liposome and probiotics encapsulated by the liposome, wherein the probiotics are fermented to produce gamma-aminobutyric acid (GABA) that alleviates the activation of an inflammatory response in substantia nigra inducedin a MPTP induced PD model, thus mitigating an inflammatory injury to dopaminergic neurons in substantia nigra and having a neuroprotective effect; encapsulation of the probiotics by the liposome can protect the probiotics from strong acids and digestive enzymes in gastric acid.

Abstract: The present disclosure provides novel synthetic intermediates useful in the synthesis of MK2 kinase inhibitors.

Abstract: Embodiments provide a seat connecting device with an adjustable backrest, belonging to the technical field of swivel chairs. In the embodiments, the seat connecting device includes a seat back tightness control assembly including a control handle, a universal joint, a transmission rod, a first bevel gear, a second bevel gear, a lifting part, a mounting seat of the lifting part, and a tightness adjust rod. The present disclosure uses the universal joint to replace the original rope for transmission, improving the response timeliness of the force transmission of the product when adjusting the seat back elasticity; and improving the accuracy and controllability of the seat back elasticity adjustment.

Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.

Abstract: Highly efficient methods are provided for preparing key intermediates in the synthesis of Compound (I), which are broadly applicable and can provide selected components having a variety of substituents groups.

Abstract: A homogenization process for coiled tubing is provided. After being preheated in a sectional manner and quenched and tempered, laser-welded low-carbon alloy steel coiled tubing is spray cooled, and then is tempered to obtain homogeneous silvery coiled tubing. Microstructural uniformity of the silvery coiled tubing after the treatment is greatly improved in a welding seam region, a heat sensing region, and a tube wall, situations in which an outer surface of the coiled tubing is burnt and oxidized in the homogenization process are reduced, and a service life of the coiled tubing is prolonged. Moreover, homogeneous coiled tubing with different yield strengths and tensile strengths can be obtained by changing a temperature of the tempering, so that production costs are reduced.

Abstract: The invention generally relates to an improved processes for the preparation of a cyclic dinucleotide which is useful as a STING agonist of the following formula (I), involving the use of compounds A and B.

Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.

Abstract: Provided are a DDoS attack detection method and apparatus. The method comprises: acquiring network traffic of a target moment within a first period by sampling, then querying a traffic period change curve acquired in advance, determining predicted traffic corresponding to the target moment, and confirming a DDoS attack if the network traffic acquired by sampling is larger than the determined predicted traffic. The traffic period change curve is used for indicating a period change law of the predicted traffic, so that before DDoS attack detection is performed at each target moment, it only needs to determine the predicted traffic corresponding to the target moment according to the traffic period change curve without calculating the predicted traffic according to massive historical traffic data before each DDoS attack detection; and the calculation volume is reduced.

Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.